Merck and Eisai trial for kidney cancer combination therapy fails endpoints

April 21, 2026 6:45 AM

Merck (NYSE: MRK) and Eisai announced that their Phase 3 LITESPARK-012 trial evaluating combination treatments for advanced renal cell carcinoma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found